9	Cancer institute August 25, 2011	Fibrillary astrocytoma, Grade 2	Regional hospital MRI June 27, 2011	Contrast-enhancing lesion in right temporo-parieto-occipital area	Partial tumor resection August 19, 2011
	Cancer institute November 22, 2011	Astrocytoma, Grade 2/3			Repeat partial tumor resection November 7, 2011
	Institute of neurology May 23, 2013	GBM			RT 5400 cGy January 16, 2012 to February 20, 2012	Cancer institute MRI February 2, 2013	Recurrence
					Repeat partial tumor resection May 15, 2013
					TMZ 5 days (28 day cycle x9) May 2013 to February 2014	Cancer institute MRI January 27, 2014	Recurrence
					PCV chemotherapy ×2 March 2014 to May 14, 2014	Cancer institute MRI May 14, 2014	Recurrence
					BC. June 19, 2014 PB, sorafenib, pazopanib, everolimus, dasatinib, BVZ			Regional radiology MRI August 28, 2014	PR	IDH1-R132H mutation, CDK4-amplification, TP53 loss (G245S), ATRX-R808 mutation EPHA3 loss (V4121) (tissue)
10	University hospital September 4, 2013	GBM	University hospital MRI August 20, 2013	Enhancing mass in the right occipital lobe	Gross tumor resection August 23, 2013. Standard RT and TMZ September 20, 2013 to November 20, 2013. TMZ, 28 day cycle December 2013 to June 30, 2014.	Regional radiology MRI July 18, 2014	Recurrence
					BC. July 28, 2014 PB, pazopanib, everolimus, dasatinib, BVZ			Regional radiology MRI September 4, 2014	CR^*	HER-2-elevated, EGFR and VEGF-normal (blood), NF1-loss of function rearrangement exxon 31, PIK3CA-H1047L mutation, CDKN2A-loss equivocal (tissue)
11	University hospital January 27, 2014	GBM	University hospital MRI January 7, 2014	Left frontal lobe tumor	Partial tumor resection January 9, 2014. Standard RT with TMZ February 28, 2014 to April 8, 2014. TMZ every 28 days May 5, 2014 to August 1, 2014.	Regional radiology August 19, 2014	Recurrence
					BC. August 18, 2014 PB, pazopanib, everolimus, dasatinib, BVZ			Regional radiology MRI September 16, 2014	PR^**	HER-2, VEGF-elevated, EGFR-normal (blood), NF1 loss-Y2885 fs^5 mutation, NF2 loss-5518 fs^4 mutation, FANCG, GATA2, HSD3B1, IKBKE, NOTCH2 mutations (tissue)